Lineage Cell rises on deal with Roche to develop, sell eye disorder therapy

Lineage Cell Therapeutics

20/12/2021 11:43

** Shares of cell therapy developer Lineage Cell
Therapeutics  LCTX.A  rise 11% to $2.36 premarket
    ** Company and its unit enter into exclusive worldwide
collaboration and license agreement with Swiss drugmaker Roche
 ROG.S  to develop and sell an eye disorder cell therapy
 urn:newsml:reuters.com:*:nBw5CnJwJa
    ** Roche's unit Genentech will pay LCTX $50 mln upfront;
LCTX is eligible to receive up to $620 mln in additional
milestone payments - LCTX
    ** LCTX says Genentech to be responsible for further
clinical development and commercialization of the therapy,
OpRegen, which is currently in an early-to-mid stage study in
patients with advanced dry age-related macular degeneration
(AMD) and geographic atrophy (GA)
    ** Lineage says it will complete activities related to the
ongoing clinical study and perform certain manufacturing
activities
    ** Dry AMD is a common eye disorder among people over 50 and
GA is its advanced form, which progressively affects vision
    ** Stock had risen 20.5% YTD, up to the last close

 (Reporting by Amruta Khandekar)
 ((Amruta.Khandekar@thomsonreuters.com;))